We have reviewed our model on ABN Amro, incorporating the NIBC acquisition, the ambitious growth targets in Wealth Management and the aggressive cost savings targets, mainly driven by FTE reductions. By FY28 we see our income estimates increase by 4.3% and cost estimates decrease by 3.1%. Our new SoTP valuation points to a target price of €29 (vs €25.5), reiterating our Hold recommendation given limited upside.
Floris Lagerwerf nominated future CFO of IMCD as of January 2027 Rotterdam, The Netherlands (12 December 2025) – IMCD N.V. ("IMCD" or "Company"), a global leading partner for the distribution and formulation of speciality chemicals and ingredients, is pleased to announce that its Supervisory Board nominates Floris Lagerwerf to become Chief Financial Officer (CFO) of IMCD as of January 2027. Floris will succeed Hans Kooijmans, who has decided to retire as per the end of December 2026. Floris started his career as external auditor in 2006, and he joined IMCD in its Rotterdam headquarters in ...
IMCD: Supervisory Board members nominated for reappointment Rotterdam, The Netherlands (12 December 2025) – “IMCD N.V. ("IMCD" or "Company"), a global leading partner for the distribution and formulation of speciality chemicals and ingredients, announces that the Supervisory Board of IMCD nominates Mr. Janus Smalbraak for reappointment as member and Chair of the Supervisory Board at the next Annual General Meeting (AGM) in 2026. In addition to the nomination of Janus Smalbraak, the Supervisory Board nominates Mr. Stephan Nanninga for a third term of two years and Mr. Willem Eelman for a sec...
The surprise call on the outlook update was only open to analysts and basically served to highlight the past 10 years of growth. Nevertheless €2.30 EPRA EPS, comes above consensus and our €2.25 estimate. Xior wants to show that after 2 years of transition and flat EPS, they will show growth again. Under COO, Kristina Olsen, Xior has also improved its internal operations and budget planning for next year had already finished. The focus is on internal efficiency gains and rental growth from realis...
Belgian Telecoms: DIGI Belgium CEO Interview: ‘We are running a marathon, not a sprint' IBA: IBA to install a Rhodotron in East China. Ontex: Another quarter, another profit warning. Theon International: Backlog visibility indeed. Xior: 2026 outlook positive but with no major surprise. Events Calendar
Today Xior celebrates its 10 year listing on the Brussels stock exchange. At the same time it issued a FY26 EPRA EPS outlook and expects EPS growth of +4% in FY26 to €2.30 vs. FY25 of €2.21. Xior is confident about the future, driven by its student housing platform and 98% occupancy. It expects rental growth from additions to its scalable operations and structural market scarcity to drive rental increases. Also efficiency gains should add to profitability gains. Xior will focus on portfolio opti...
ABN AMRO announces significant risk transfer transaction with Blackstone ABN AMRO announces significant risk transfer transaction with Blackstone 11 December 2025 Today, ABN AMRO announces a significant risk transfer (SRT) transaction with funds manged by Blackstone. This transaction provides first loss protection on a EUR 2 billion portfolio of large corporate loans. The transaction underscores our commitment to creating more room for further profitable growth by actively managing portfolios. We expect the transaction will reduce the bank's risk-weighted assets by EUR 1.6 billion, while...
ABN AMRO kondigt significante risico-overdrachtstransactie aan met Blackstone ABN AMRO kondigt significante risico-overdrachtstransactie aan met Blackstone 11 december 2025 Vandaag kondigt ABN AMRO een significante risico-overdrachtstransactie (SRT) aan met fondsen beheerd door Blackstone. Deze transactie biedt bescherming tegen eerste verliezen op een portefeuille van EUR 2 miljard aan leningen aan grote bedrijven. De transactie onderstreept onze toewijding om actief onze portefeuilles te beheren en meer ruimte te creëren voor verdere winstgevende groei. We verwachten dat de transactie ...
Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025 Data show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients dosed with 100 million cellsAll patients show deep B-cell depletion after infusion, suggesting an immune resetNine patients were evaluable for safety, no ICANS or high-grade CRS were observed LONDON and GAITHERSBURG, Md., Dec. 08, 2025 (GLOBE NE...
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025 Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) observed, consistent with obe-cel’s adult safety profile FELIX study data analyses highlight product cell phenotype and level of CAR T persistence at three months as pote...
Autolus Therapeutics Appoints Ryan Richardson to Board of Directors LONDON and GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced the appointment of Ryan Richardson to the Company’s Board of Directors. Mr. Richardson brings more than 20 years of strategy and corporate development experience and in the healthcare and investment banking industries to Autolus’ Board. “Autolus has entered a new pha...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.